Literature DB >> 15979918

Cardiac manifestations in the mouse model of mucopolysaccharidosis I.

Maria C Jordan1, Yi Zheng, Sergey Ryazantsev, Nora Rozengurt, Kenneth P Roos, Elizabeth F Neufeld.   

Abstract

Mucopolysaccharidosis I (MPS I, alpha-l-iduronidase deficiency disease) is a heritable lysosomal storage disorder involving multiple organs, including the heart. Malfunction of the heart is also a major manifestation in the mouse model of MPS I, progressing in severity from 6 to 10 months (of a 1 year life span). In comparisons of MPS I with wild-type mice, the heart was found enlarged, with thickened septal and posterior walls, primarily because of infiltration of the muscle by storage-laden cells. Heart valves were enlarged and misshapen, and contained large numbers of highly vacuolated interstitial cells. The thickened aortic wall contained vacuolated smooth muscle cells and interrupted elastic fibers. Hemodynamic measurements and echocardiography revealed reduced left ventricular function as well as mitral and aortic regurgitation. But despite these abnormalities, free-roaming MPS I mice implanted with radio telemetry devices showed surprisingly normal heart rate and blood pressure, though their electrocardiograms were abnormal. An incidental finding of the telemetry studies was a disturbed circadian rhythm in the MPS I mice. Restoration of enzyme activity in the heart of one mouse, by transplantation of retrovirally modified bone marrow, resulted in normalization of left ventricular function as well as loss of storage vacuoles in myocytes and endothelial cells, though not in valvular interstitial cells. This study demonstrates the usefulness of the mouse model for in-depth studies of the cardiovascular component of MPS I.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15979918      PMCID: PMC1369003          DOI: 10.1016/j.ymgme.2005.05.003

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  30 in total

1.  Disordered breathing during sleep in patients with mucopolysaccharidoses.

Authors:  S E Leighton; B Papsin; A Vellodi; R Dinwiddie; R Lane
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2001-04-27       Impact factor: 1.675

2.  Hurler's syndrome with cor pulmonale secondary to obstructive sleep apnoea treated by continuous positive airway pressure.

Authors:  D Chan; A M Li; M C Yam; C K Li; T F Fok
Journal:  J Paediatr Child Health       Date:  2003 Sep-Oct       Impact factor: 1.954

Review 3.  The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I.

Authors:  James Edward Wraith
Journal:  Expert Opin Pharmacother       Date:  2005-03       Impact factor: 3.889

4.  Cardiac arrhythmias: from (transgenic) mice to men.

Authors:  B London
Journal:  J Cardiovasc Electrophysiol       Date:  2001-09

5.  Phenotypic screening for heart rate variability in the mouse.

Authors:  J Gehrmann; P E Hammer; C T Maguire; H Wakimoto; J K Triedman; C I Berul
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-08       Impact factor: 4.733

6.  Enzyme-replacement therapy in mucopolysaccharidosis I.

Authors:  E D Kakkis; J Muenzer; G E Tiller; L Waber; J Belmont; M Passage; B Izykowski; J Phillips; R Doroshow; I Walot; R Hoft; E F Neufeld
Journal:  N Engl J Med       Date:  2001-01-18       Impact factor: 91.245

7.  Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB.

Authors:  Kazuhiro Ohmi; David S Greenberg; Kavitha S Rajavel; Sergey Ryazantsev; Hong Hua Li; Elizabeth F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

8.  Cardiovascular changes in children with mucopolysaccharide disorders.

Authors:  U R Mohan; A A Hay; M A Cleary; J E Wraith; R G Patel
Journal:  Acta Paediatr       Date:  2002       Impact factor: 2.299

9.  Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow.

Authors:  Yi Zheng; Nora Rozengurt; Sergey Ryazantsev; Donald B Kohn; Noriko Satake; Elizabeth F Neufeld
Journal:  Mol Genet Metab       Date:  2003-08       Impact factor: 4.797

10.  Human Gene Mutation Database (HGMD): 2003 update.

Authors:  Peter D Stenson; Edward V Ball; Matthew Mort; Andrew D Phillips; Jacqueline A Shiel; Nick S T Thomas; Shaun Abeysinghe; Michael Krawczak; David N Cooper
Journal:  Hum Mutat       Date:  2003-06       Impact factor: 4.878

View more
  27 in total

1.  Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation.

Authors:  Guilherme Baldo; Susan Wu; Ruth A Howe; Meera Ramamoothy; Russell H Knutsen; Jiali Fang; Robert P Mecham; Yuli Liu; Xiaobo Wu; John P Atkinson; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2011-08-24       Impact factor: 4.797

2.  Cardiac disease in mucopolysaccharidosis type I attributed to catecholaminergic and hemodynamic deficiencies.

Authors:  Nathan J Palpant; Fikru B Bedada; Brandon Peacock; Bruce R Blazar; Joseph M Metzger; Jakub Tolar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-12       Impact factor: 4.733

3.  Laronidase replacement therapy and left ventricular function in mucopolysaccharidosis I.

Authors:  Haruhito Harada; Hiroshi Niiyama; Atsushi Katoh; Hisao Ikeda
Journal:  JIMD Rep       Date:  2014-05-22

4.  Gene therapy for cardiovascular manifestations of lysosomal storage diseases.

Authors:  Meg M Sleeper; Mark E Haskins; Katherine P Ponder
Journal:  Heart Metab       Date:  2008

5.  Autocrine VEGF signaling is required for vascular homeostasis.

Authors:  Sunyoung Lee; Tom T Chen; Chad L Barber; Maria C Jordan; Jared Murdock; Sharina Desai; Napoleone Ferrara; Andras Nagy; Kenneth P Roos; M Luisa Iruela-Arispe
Journal:  Cell       Date:  2007-08-24       Impact factor: 41.582

6.  Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy.

Authors:  Mayra F Garcia-Rivera; Leah E Colvin-Wanshura; Matthew S Nelson; Zhenhong Nan; Shaukat A Khan; Tyson B Rogers; Indrani Maitra; Walter C Low; Pankaj Gupta
Journal:  Brain Res Bull       Date:  2007-08-06       Impact factor: 4.077

7.  Gender-related dimorphism in aortic insufficiency in murine mucopolysaccharidosis type I.

Authors:  Jakub Tolar; Elizabeth Braunlin; Megan Riddle; Brandon Peacock; Ron T McElmurry; Paul J Orchard; Bruce R Blazar
Journal:  J Heart Valve Dis       Date:  2009-09

8.  Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice.

Authors:  Xiucui Ma; Mindy Tittiger; Russell H Knutsen; Attila Kovacs; Laura Schaller; Robert P Mecham; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2008-05-13       Impact factor: 4.797

9.  Biventricular adaptation to volume overload in mice with aortic regurgitation.

Authors:  Christopher J Berry; Jordan D Miller; KellyAnn McGroary; Daniel R Thedens; Stephen G Young; Donald D Heistad; Robert M Weiss
Journal:  J Cardiovasc Magn Reson       Date:  2009-08-11       Impact factor: 5.364

10.  Cardiac abnormalities in adults with the attenuated form of mucopolysaccharidosis type I.

Authors:  O I I Soliman; R G M Timmermans; A Nemes; W B Vletter; J H P Wilson; F J ten Cate; M L Geleijnse
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.